International Journal of Hematology-Oncology and Stem Cell Research 2005. 2(2):1-4.

A Survey of 121 patients with Idiopathic Thrombocytopenic Purpura
A Shahriariahmadi, M Tahmasian


Introduction: Idiopathic Thrombocytopenic Purpura is one of the most common causes of thrombocy-topenia with varius clinical courses and different responses to its treatment modalities. Therefore, we decided to evaluate the clinical course of this disease in our patients.
Methods: In this case series study, from March 1998 to March 2004, we evaluated 121 patients. As a first line of treatment, all of those patients received prednisolone (1mg/kg/day) for 6 weeks. Those who didn't respond or were refractory to prednisolone were candidates for splenectomy, and those who re¬fused these modalities or didn't respond to them were treated with Azathioprine.
Results: 99 patients (81.8%) were female and 22 (18.2%) were male, aged 11-73 years (mean; 28.6). Two patients had immune hemolytic anemia in addition to thrombocytopenia, 4 had systemic lupus erythematosus, and one was HIV positive. %44.6 of patients fully responded to prednisolone, 42 pa¬tients (%34.7) underwent splenectomy and %83.3 of them responsed to it.31 splenectomies were per¬formed in the first three months after diagnosis and 27 (87.1%) of them showed complete response, but 8 (72.7%) of the patients splenectomized after 3 months, had complete response. 14 patients were treated with Azathoprine, 2 of which (14.3%) platelet count normalized.
Conclusion: ITP is more common in females than males. Prednisolone is preferred as a non-invasive treatment with suitable response in comparison to other modalition responses to splenectomy, indicat¬ing that this modality of treatment is useful and effective, especially when performaed in the first 3 months of the diseases.


Idiopathic thrombocytopenic purpura(ITP); Prednisolone; Azathioprine

Full Text:



Sandler SG, Review: Immune thrombocytopenic pur- pura: an update for immuno hematologists. Immunohe- matol 2004; 20(2): 112-117.

Wong GC, Lee LH. A study of idiopathic thrombocy- topenic purpura (ITP) patients over a ten- year period. Ann Acad Med singapor 1998; 27(6): 789-793.

Handin R, Disorders of the platelet and vessel wall. In: Braunwald E, Fauci A, kasper D etal. Harrison's princi- ples of internal medicine. PA: MCGraw –Hill; 2005:746.

Bussel J, Cines D: Immune thrombocytopenic purpura, Neonatal Alloimmune thrombocytopenia and post trans- fusion purpura In: Hoffman R, Benz EJ, Furie B et al. Hematology Basic Principle and practice. PA: Churchill Livingstone 2000; 2096.

Diagnosis and treatment of idiopathic thrombocyto- penic purpura: recommendation of the american society of hematology. Annual of internal medicine 126(4): 319- 326.

Gills S. The thrombocytopenic purpura recognition and management. Drugs 1996; 51(6): 942-953

Sandler SG, Tutuncyglu SO. Immune thrombocyto- penic purpura –Current management practices. Expert opin Pharmacother 2004; 5(12): 2515-2527.

George JN, Raskob GE. Clinical decisions in idio- pathic thrombocytopenic purpura. Hosp Pract (offed) 1997; 32(9): 159-160, 163-166, 169-170.

Bedri A, Abebe E. Idiopathic thrombocytopenic pur- pura (ITP)in Ethiopian chidren : clinical findings and re- sponse to therapy. Ethiop Med J 1995; 33(2): 75-81.

George JN, Raskob GE. Idiopathic thrombocyto- penia purpura: diagnosis and managmenet. Am J Med Sci 1998; 316(2):87-93.

Michel M, Chanet V, Galicier L et al. Autoimmure thrombocytopenic purpura and common variable immu- nodeficiency: analysis of 21 cases and review of the lit- erature. Medicine (Baltimor) 2004; 83(4): 254-263.

Ohmine K, Izumi T, Muriok et al. Low –dose pred- misolone therapy for idiopathic thromabocytopenic pur- pura. Rinsho ketsueki 2000; 41(1):8-11.

Jackson N, Mustapha M, Baba AA. Adult idiopathic thtrombocytope purpura without the option of splenec- tomy. Med J Malaysia 1995; 50(3): 250-255.

Kojouri K, Vesely SK, Terrell DR et al. Splenec- tomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count response, prediction of response and surgical com- plications. Blood 2004; 104(9): 2623-2634.

Berends FJ, Schep N, Cuesta MA et al. Hematologi- cal long-term results of laparascopic splenectomy for pa- tients with idiopathic thrombocytopenic purpura: a case control study. Surg Endosc 2004; 18(5): 766-770.

Ismet A , Irfan K, Emin K etal. Splenectomy results in patients with idiopathic thrombocytopenic: 10 years of experience in Turgut ozal Medical Center. Clin lab Hea- matol 2004; 26(3): 211-2147.

Vesely SK, Perdue JJ, Rizvi MA et al. Management of adult patients with persistent idiopathic thrombocyto- penic purpura following splenectomy: a systemic review. Ann Intern Med 2004; 140(2): 112-120.

Stasi R, Provan D. Management of immune throm- bocytopenic purpura in adults. Mayo clin Pro 2004; 79(4):504-522.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.